Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Ezra E.W. Cohen,Lisle Nabell,Deborah J.L. Wong,Terry A. Day,Gregory A. Daniels,Mohammed M. Milhem,Sanjeev Deva,Michael B. Jameson,Orlando Guntinas-Lichius,Mohammed Almubarak,Robert Matthew Strother,Eric D. Whitman,Michael Jon Chisamore,Cynthia Chinedu Obiozor,Teresa Bagulho,Albert Candia,Erick Gamelin,Robert S. Janssen,Alain Patrick Algazi

Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

2019

Ezra E.W. Cohen
Lisle Nabell
Deborah J.L. Wong
Terry A. Day
Gregory A. Daniels
Mohammed M. Milhem
Sanjeev Deva
Michael B. Jameson
Orlando Guntinas-Lichius
Mohammed Almubarak
Robert Matthew Strother
Eric D. Whitman
Michael Jon Chisamore
Cynthia Chinedu Obiozor
Teresa Bagulho
Albert Candia
Erick Gamelin
Robert S. Janssen
Alain Patrick Algazi

6039Background: SD-101, a synthetic CpG-ODN agonist of TLR9, stimulates dendritic cells to release IFN-alpha and mature into antigen presenting cells - activating T cell anti-tumor responses. Pembr...

Keywords:

Head and neck squamous-cell carcinoma
Medicine
Antigen-presenting cell
TLR9
multicenter study
Pembrolizumab
T cell
Cancer research
Agonist
anti pd 1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations